Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | phospholipase A1, putative | 0.3245 | 1 | 1 |
Schistosoma mansoni | amine GPCR | 0.1335 | 0 | 0.5 |
Onchocerca volvulus | 0.3245 | 1 | 0.5 | |
Onchocerca volvulus | 0.3245 | 1 | 0.5 | |
Loa Loa (eye worm) | platelet-activating factor acetylhydrolase | 0.3245 | 1 | 0.5 |
Onchocerca volvulus | 0.3245 | 1 | 0.5 | |
Leishmania major | phospholipase A1, putative | 0.3245 | 1 | 0.5 |
Trypanosoma brucei | phospholipase A1, putative | 0.3245 | 1 | 0.5 |
Trypanosoma cruzi | phospholipase A1, putative | 0.3245 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (binding) | > 112.219 um | PUBCHEM_BIOASSAY: Luminescence Biochemical Dose Response HTS to Identify Inhibitors of Luciferase. (Class of assay: confirmatory) [Related pubchem assays: 1663 (Primary HTS), 1678 (Summary of Project)] | ChEMBL. | No reference |
Potency (binding) | = 28.1838 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.